Medicines Co. buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 25.01.18 mit einem Endkurs von 29,14 € beendet. Die Einschätzung zu Medicines Co. enttäuschte mit einer Rendite von -24,86 %. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Medicines Co. | - | - | - | - |
| iShares Core DAX® | 0,96 % | -2,21 % | 12,84 % | 17,15 % |
| iShares Nasdaq 100 | 2,63 % | -1,92 % | 38,50 % | 45,46 % |
| iShares Nikkei 225® | 0,22 % | -7,22 % | 19,42 % | 5,08 % |
| iShares S&P 500 | 1,54 % | -1,86 % | 27,80 % | 42,58 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Medicines Co. diskutieren
klostergang stimmt der Outperform-Einschätzung der institutionellen Analysten zu
The Medicines Company announced that its Phase 3 clinical trial, TANGO-2, evaluating QIDP- and Fast Track-tagged Vabomere (meropenem-vaborbactam) for the treatment of complex carbapenem-resistant Enterobacteriaceae (CRE) infections has been stopped early after demonstrating a significant therapeutic benefit.
The independent Data and Safety Monitoring Board (DSMB) concluded that Vabomere's (formerly known as Carbavance) benefit/risk profile no longer supported randomization of additional
patients to the best available therapy comparator arm. Its recommendation was based on the analysis of 72 patients, including 43 with evaluable CRE infections of blood, lung, urinary tract and
abdominal organs.
Detailed data will be submitted for presentation at a future medical conference and for publication.
The company's U.S. marketing application was accepted for review by the FDA in February with an action date this quarter. Its marketing application in Europe was accepted for review by the EMA in July.